Durvalumab

Human IgG1 kappa

Flow cytometry analysis of PD-L1 overexpression CHO cells labelling PD-L1 with Durvalumab at 20 nM (Red). Goat anti human IgG Fc (Alexa Fluor488) was used as the secondary antibody at 1/1000 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells (Gray).

Durvalumab purchased from MedChemExpress. Usage Cited in: Preprints. 10 May 2022.

Customer Validation
Migration-focused results of ECIS tests on T98G and U87 glioblastoma cells treated with Radiation and Durvalumab. Representative plot of normalized resistance in the first 40 hours posttreatment for T98G.

Durvalumab purchased from MedChemExpress. Usage Cited in: Preprints. 10 May 2022.

Customer Validation
Barrier function-focused results of ECIS tests on T98G glioblastoma cells treated with radiation and durvalumab. Representative plot of the barrier function Rb posttreatment for T98G shown.

Durvalumab purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2020 Dec;10(12):1872-1893. [Abstract]

Customer Validation
4T1-hPD-L, where the basal mouse PD-L1 was knocked out followed by adding back human PD-L1 gene, and 4T1-hB7-H4 cells were orthotopically injected into the left fourth mammary fat pad and allow to grow around 100 mm3, followed by injection of Cam (25 mg/kg, i.p.) for 4 times, NGI-1 nanoparticle (10 mg/kg, i.v.) as well as PD-L1 antibody Durvalumab (5 mg/kg, i.p.) for 3 times. The tumor growth was monitored twice per week. n=8 mice per group.

Durvalumab purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2020 Dec;10(12):1872-1893. [Abstract]

Customer Validation
Survival curve of the mice of the combination of Cam, NGI-1 nanoparticle and Durvalumab (5 mg/kg, i.p., 3 times). n=8 mice per group.

Durvalumab purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2020 Dec;10(12):1872-1893. [Abstract]

Customer Validation
4T1-hPD-L, where the basal mouse PD-L1 was knocked out followed by adding back human PD-L1 gene, and 4T1-hB7-H4 cells were orthotopically injected into the left fourth mammary fat pad and allow to grow around 100 mm3, followed by injection of Cam (25 mg/kg, i.p.) for 4 times, NGI-1 nanoparticle (10 mg/kg, i.v.) as well as PD-L1 antibody Durvalumab (5 mg/kg, i.p.) for 3 times. Tumor tissues were subjected to the immunohistochemically staining with anti-CD8 antibody.